Impaired Retinal Circulation during Axitinib Treatment for Metastatic Renal Cell Carcinoma

PURPOSE: Axitinib, an orally administered vascular endothelial growth factor receptors 1, 2, and 3 inhibitor, is widely used as the second-line treatment for metastatic renal cell carcinoma. We present a case of metastatic renal cell carcinoma who developed a novel ocular adverse event, impaired ret...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimura, Masashi, Kusuhara, Sentaro, Tagami, Mizuki, Nakamura, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489367/
https://www.ncbi.nlm.nih.gov/pubmed/31097940
http://dx.doi.org/10.1159/000496197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489367/
https://www.ncbi.nlm.nih.gov/pubmed/31097940
http://dx.doi.org/10.1159/000496197

Ejemplares similares